CA3246977A1 - ALKALINE INTRAORAL FORMULATIONS - Google Patents

ALKALINE INTRAORAL FORMULATIONS

Info

Publication number
CA3246977A1
CA3246977A1 CA3246977A CA3246977A CA3246977A1 CA 3246977 A1 CA3246977 A1 CA 3246977A1 CA 3246977 A CA3246977 A CA 3246977A CA 3246977 A CA3246977 A CA 3246977A CA 3246977 A1 CA3246977 A1 CA 3246977A1
Authority
CA
Canada
Prior art keywords
nicotine
chemically bonded
bonded ceramic
formulation
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246977A
Other languages
English (en)
French (fr)
Inventor
Håkan Engqvist
Jesper Lööf
Original Assignee
Emplicure Publ AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2204804.5A external-priority patent/GB2613211B/en
Priority claimed from GBGB2208807.4A external-priority patent/GB202208807D0/en
Application filed by Emplicure Publ AB filed Critical Emplicure Publ AB
Publication of CA3246977A1 publication Critical patent/CA3246977A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B13/00—Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Tobacco Products (AREA)
CA3246977A 2022-04-01 2023-04-03 ALKALINE INTRAORAL FORMULATIONS Pending CA3246977A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2204804.5 2022-04-01
GB2204804.5A GB2613211B (en) 2022-04-01 2022-04-01 Alkaline oral formulations
GBGB2208807.4A GB202208807D0 (en) 2022-06-15 2022-06-15 Alkaline intraoral formulations
GB2208807.4 2022-06-15
PCT/EP2023/058713 WO2023187224A1 (en) 2022-04-01 2023-04-03 Alkaline intraoral formulations

Publications (1)

Publication Number Publication Date
CA3246977A1 true CA3246977A1 (en) 2023-10-05

Family

ID=86096079

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246977A Pending CA3246977A1 (en) 2022-04-01 2023-04-03 ALKALINE INTRAORAL FORMULATIONS

Country Status (7)

Country Link
US (1) US20250228770A1 (https=)
EP (1) EP4504146B1 (https=)
JP (1) JP2025513763A (https=)
CN (1) CN119136784A (https=)
CA (1) CA3246977A1 (https=)
MX (1) MX2024012083A (https=)
WO (1) WO2023187224A1 (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9848634B2 (en) * 2009-06-30 2017-12-26 Philip Morris Products S.A. Smokeless tobacco product
CN101966165B (zh) * 2009-07-14 2012-06-13 无锡健而乐医药科技有限公司 口腔吸收固体泡腾制剂
SE535587C2 (sv) 2011-03-29 2012-10-02 Chill Of Sweden Ab Produkt innehållande ett fritt nikotinsalt och en ej vattenlöslig påse
CN103284318B (zh) * 2013-06-20 2015-03-11 中国烟草总公司山东省公司 一种舌下烟及其制备方法
WO2015193379A1 (en) * 2014-06-18 2015-12-23 Swedish Match North Europe Ab A tobacco or non-tobacco product comprising magnesium carbonate
CN107259635A (zh) * 2017-06-16 2017-10-20 云南中烟工业有限责任公司 一种烟碱复合盐含化片及其制备方法
GB201714412D0 (en) * 2017-09-07 2017-10-25 Emplicure Ab Evaporation devices containing plant material
WO2019110073A1 (en) 2017-12-08 2019-06-13 Fertin Pharma A/S Solid oral nicotine formulation
CA3085065C (en) * 2017-12-08 2023-12-05 Fertin Pharma A/S Formulations providing high nicotine concentrations
JP2022519542A (ja) * 2019-02-01 2022-03-24 スウィーディッシュ・マッチ・ノース・ヨーロップ・アーベー ｐＨ調整剤を含む経口用ニコチン製品
US20210169123A1 (en) * 2019-12-09 2021-06-10 Nicoventures Trading Limited Pouched products with enhanced flavor stability
GB202105305D0 (en) * 2021-04-14 2021-05-26 Zanoprima Lifesciences Ltd Supported nicotine composition

Also Published As

Publication number Publication date
WO2023187224A1 (en) 2023-10-05
US20250228770A1 (en) 2025-07-17
EP4504146A1 (en) 2025-02-12
MX2024012083A (es) 2025-01-09
JP2025513763A (ja) 2025-04-30
EP4504146B1 (en) 2025-12-17
CN119136784A (zh) 2024-12-13
EP4504146C0 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
CN103491958B (zh) 含有呈游离盐形式的烟碱的小袋
DK2830622T3 (en) NICOTINE PRODUCT FOR ORAL ADMINISTRATION CONTAINING A POWDER CONTAINED IN A VANDU-SOLUBLE BAG, WHICH POWDER CONTAINS NICOTINE AND A CHEMICAL GUM COMPOSITION
JP2022538696A (ja) ニコチン含有粒子を含有する充填材を含む経口袋状ニコチン製品
US20250280866A1 (en) Nicotine formulations
CA2868445C (en) Nicotine formulation
EP4504146B1 (en) Alkaline intraoral formulations
GB2620110A (en) Alkaline intraoral products
GB2619747A (en) Nicotine formulations
GB2613211A (en) Alkaline oral formulations
US20250228771A1 (en) Alkaline intraoral products

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241029

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241029

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241029

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241114

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260316

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260316

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260423